Literature DB >> 10864195

Immune selection in neoplasia: towards a microevolutionary model of cancer development.

S J Pettit1, K Seymour, E O'Flaherty, J A Kirby.   

Abstract

The dual properties of genetic instability and clonal expansion allow the development of a tumour to occur in a microevolutionary fashion. A broad range of pressures are exerted upon a tumour during neoplastic development. Such pressures are responsible for the selection of adaptations which provide a growth or survival advantage to the tumour. The nature of such selective pressures is implied in the phenotype of tumours that have undergone selection. We have reviewed a range of immunologically relevant adaptations that are frequently exhibited by common tumours. Many of these have the potential to function as mechanisms of immune response evasion by the tumour. Thus, such adaptations provide evidence for both the existence of immune surveillance, and the concept of immune selection in neoplastic development. This line of reasoning is supported by experimental evidence from murine models of immune involvement in neoplastic development. The process of immune selection has serious implications for the development of clinical immunotherapeutic strategies and our understanding of current in vivo models of tumour immunotherapy.

Entities:  

Mesh:

Year:  2000        PMID: 10864195      PMCID: PMC2363247          DOI: 10.1054/bjoc.2000.1206

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  68 in total

Review 1.  BCG immunotherapy of bladder cancer: 20 years on.

Authors:  A B Alexandroff; A M Jackson; M A O'Donnell; K James
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.

Authors:  A Melcher; S Todryk; N Hardwick; M Ford; M Jacobson; R G Vile
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

4.  Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake.

Authors:  S Todryk; A A Melcher; N Hardwick; E Linardakis; A Bateman; M P Colombo; A Stoppacciaro; R G Vile
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

5.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Authors:  P P Lee; C Yee; P A Savage; L Fong; D Brockstedt; J S Weber; D Johnson; S Swetter; J Thompson; P D Greenberg; M Roederer; M M Davis
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

6.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

Authors:  E van de Wiel-van Kemenade; M J Ligtenberg; A J de Boer; F Buijs; H L Vos; C J Melief; J Hilkens; C G Figdor
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

Review 7.  Natural history of HLA expression during tumour development.

Authors:  F Garrido; T Cabrera; A Concha; S Glew; F Ruiz-Cabello; P L Stern
Journal:  Immunol Today       Date:  1993-10

8.  Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.

Authors:  G A Gastl; J S Abrams; D M Nanus; R Oosterkamp; J Silver; F Liu; M Chen; A P Albino; N H Bander
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

9.  Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck.

Authors:  J C Pena; C B Thompson; W Recant; E E Vokes; C M Rudin
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

10.  Identification of human cancers deficient in antigen processing.

Authors:  N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Generation of MHC class I ligands in the secretory and vesicular pathways.

Authors:  Margarita Del Val; Salvador Iborra; Manuel Ramos; Silvia Lázaro
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

Review 2.  Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap.

Authors:  Evgeniy B Eruslanov; Sunil Singhal; Steven M Albelda
Journal:  Trends Cancer       Date:  2017-01-19

3.  Complement factor H-deficient mice develop spontaneous hepatic tumors.

Authors:  Jennifer Laskowski; Brandon Renner; Matthew C Pickering; Natalie J Serkova; Peter M Smith-Jones; Eric T Clambey; Raphael A Nemenoff; Joshua M Thurman
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

4.  Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.

Authors:  Sunil Singhal; Jason Stadanlick; Michael J Annunziata; Abhishek S Rao; Pratik S Bhojnagarwala; Shaun O'Brien; Edmund K Moon; Edward Cantu; Gwenn Danet-Desnoyers; Hyun-Jeong Ra; Leslie Litzky; Tatiana Akimova; Ulf H Beier; Wayne W Hancock; Steven M Albelda; Evgeniy B Eruslanov
Journal:  Sci Transl Med       Date:  2019-02-13       Impact factor: 17.956

Review 5.  [Influence of anesthesia procedure on malignant tumor outcome].

Authors:  K Fukui; C Werner; G Pestel
Journal:  Anaesthesist       Date:  2012-03       Impact factor: 1.041

Review 6.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

7.  Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes.

Authors:  Elena Afrimzon; Assaf Deutsch; Yana Shafran; Naomi Zurgil; Judith Sandbank; Itzhak Pappo; Mordechai Deutsch
Journal:  Clin Exp Metastasis       Date:  2008-01-16       Impact factor: 5.150

8.  A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability.

Authors:  Shingo Iwami; Hiroshi Haeno; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2012-02-16       Impact factor: 4.475

Review 9.  Chronic immune activation and inflammation as the cause of malignancy.

Authors:  K J O'Byrne; A G Dalgleish
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

Review 10.  Immune gene therapy in urology.

Authors:  Ingo Kausch; Peter Ardelt; Andreas Böhle; Timothy L Ratliff
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.